@article{1b982d6773d943768f744040183b877a,
title = "Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody",
author = "Whyte, {Michael P.}",
note = "Funding Information: In this issue of , Jan de Beur and colleagues report the primary analysis and findings up to closure of their prospective, open‐label, single‐arm, phase 2 study (NCT02304367) to evaluate the safety and efficacy of burosumab‐twza for treating adults with a debilitating disorder, tumor‐induced osteomalacia (TIO). Burosumab is the fully human monoclonal antibody against the phosphatonin fibroblast growth factor‐23 (FGF23). Their clinical trial was sponsored and funded by Ultragenyx Pharmaceutical, Inc., in partnership with Kyowa Kirin International, plc (UX023T‐CL201). JBMR ( 1 ) ",
year = "2021",
month = apr,
doi = "10.1002/jbmr.4280",
language = "English",
volume = "36",
pages = "625--626",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
number = "4",
}